References
- Cohn EJ, Oncley JL, Strong LE, et al. (1944). Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma. J Clin Invest, 23, 417–32
- Delves PJ, Roitt IM. (2000). The immune system. N Engl J Med, 343, 108–17
- Food and Drug Administration. (2015). Vaccines, blood, and biologics. http://www.fda.gov/BiologicsBloodVaccines/
- Gates B. (2015). The next epidemic – lessons from Ebola. N Engl J Med, 372, 1381–4
- Hegde NR, Rao PP, Bayry J, Kaveri SV. (2009). Immunotherapy of viral infections. Immunotherapy, 1, 691–711
- Helbig ET, Opitz B, Sander LE. (2013). Adjuvant immunotherapies as a novel approach to bacterial infections. Immunotherapy, 5, 365–81
- Hemming VG. (2001). Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol, 8, 859–63
- Kata A. (2010). A postmodern Pandora’s box: Anti-vaccination misinformation on the Internet. Vaccine, 28, 1709–16
- Kata A. (2012). Anti-vaccine activists, Web 2.0, and the postmodern paradigm–an overview of tactics and tropes used online by the anti-vaccination movement. Vaccine, 30, 3778–89
- Kaufmann GF, Park J, Janda KD. (2008). Bacterial quorum sensing: A new target for anti-infective immunotherapy. Expert Opin Biol Ther, 8, 719–24
- Laxminarayan R, Jamison DT, Krupnick AJ, Norheim OF. (2014). Valuing vaccines using value of statistical life measures. Vaccine, 32, 5065–70
- Leffler DA, Lamont JT. (2015). Clostridium difficile infection. N Engl J Med, 372, 1539–48
- Lowy I, Molrine DC, Leav BA, et al.(2010). Treatment with monoclonal antibodies against clostridium difficile toxins. N Engl J Med, 362, 197–205
- Lund E, Rasmussen P. (1966). Omni-serum. A diagnostic Pneumococcus serum, reacting with the 82 known types of Pneumococcus. Acta Pathol Microbiol Scand, 68, 458–60
- Mackay IR, Rosen FS, Kazatchkine MD, Kaveri SV. (2001). Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med, 345, 747–55
- Meltzer MI. (2008). Health economics and prioritising health care. Lancet, 372, 612–3
- Mundasad S. (2015). British medic declared free of Ebola. BBC News
- Mupapa K, Massamba M, Kibadi K, et al. (1999). Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis, 179, S18–23
- Qiu X, Wong G, Audet J, et al. (2014). Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature, 514, 47–53
- Roehr B. (2012). Media induced anti-vaccination sentiment can even affect health workers, vaccine researcher says. BMJ, 344, e1563
- Roux D, Pier GB, Skurnik D. (2012). Magic bullets for the 21st century: The reemergence of immunotherapy for multi- and pan-resistant microbes. J Antimicrob Chemother, 67, 2785–7
- Salisbury G, Salisbury L. (2003). The cruelest miles. New York, NY: W.W. Norton
- van der Burg SH, Arens R, Melief CJ. (2011). Immunotherapy for persistent viral infections and associated disease. Trends Immunol, 32, 97–103
- WHO ERT. (2014). Ebola virus disease in West Africa – the first 9 months of the epidemic and forward projections. N Engl J Med, 371, 1481–95
- Zolla S, Goodman JW. (1968). An aggregating immunoglobulin in hyperimmune equine anti-pneumococcal sera. J Immunol, 100, 880–97